Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon May 24, 2021 11:16am
193 Views
Post# 33256891

RE:RE:Citagenix Inc

RE:RE:Citagenix Inc
GameChangerBet wrote:
WalkOverTheStrt wrote: Anyone hear the latest on Citagenix Inc and whether they plan to still overload this cash drain (athough metrics has imprved lately)?  


Their goal is to have it divested this year.


Agree - a good chance they divest in 2021 if market conditions are good enough to strike a deal.

Also, not sure how much of a "cash drain" Citagenix actually is.  I haven't looked at the details but If Citagenix is asked to work within some tight spending restrictions, it wouldn't be much of a drain.  For example, I assume all the R&D costs belong to ATE while all of the Selling/Marketing costs belong to CITA.  Then it's a matter of how the G&A is actually broken up.  If you assume a 90/10 split, (10% for CITA) there's no drain.  If you assume an 85/15 split there's a small drain but depreciation and amortizations may take to almost a no drain.  Once the G&A split gets to 80/20 (20% to CITA), then we can talk about some drain occurring).

Just not sure how much G&A is required for that small crew of resellers - just wondering.
<< Previous
Bullboard Posts
Next >>